ClinicalTrials.gg
RecruitingNCT07467993STAR-1Updated Jul 29, 2026

Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia

A Phase 2 interventional study of GXV813 and Placebo in Schizophrenia, sponsored by Novartis Pharmaceuticals. Recruiting at 16 sites in 2 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-07-29.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
142
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies in Schizophrenia by Novartis — 2 open to participants now, 2 under way, none of them phase 3. Schizophrenia · Novartis.

Planned enrollment
3rd of 10
142 · median 75
Started
2026
with 1 other
Phase 2
5 of 10
1 open now
Registered
9th of 10
by date

Among the 10 studies in Schizophrenia by Novartis, this one is the 3rd largest by planned enrollment, is one of 2 that started in 2026, is one of 5 in phase 2, and was the 9th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

2 of the 10 studies in Schizophrenia by Novartis are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Schizophrenia by Novartis, or all of them as a file.
02

Study summary

The purpose of this study is to assess the efficacy, safety, and tolerability of GXV813 in the treatment of an acute episode of schizophrenia

03

Conditions studied

  • Schizophrenia

Browse trials for

Keywords

  • Schizophrenia
  • GVX813
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participant is aged 18 to 65 years, inclusive, at screening
  2. Participant is capable of providing
  3. Participant has a primary diagnosis of schizophrenia, established by a comprehensive psychiatric evaluation based on the (American Psychiatric Association 2013) criteria and confirmed by Structured Clinical Interview for DSM-5 Clinical Trials version (SCID-5-CT)
  4. Participant is willing and able to be confined to an inpatient setting for the study duration (except for the follow-up period), follow instructions, and comply with the protocol requirements
  5. Participant is experiencing an acute exacerbation or relapse of psychotic symptoms, with onset less than 2 months before screening

    1. The participant requires hospitalization for this acute exacerbation or relapse of symptoms
    2. If already an inpatient at screening, has been hospitalized for less than 2 weeks for the current exacerbation at the time of screening
  6. Positive and Negative Syndrome Scale total score between 80 and 120, inclusive, at screening a. Score of ≥ 4 (moderate or greater) for ≥ 2 of the following Positive Scale (P) items:

    i. Item 1 (P1; delusions)

ii. Item 2 (P2; conceptual disorganization)

iii. Item 3 (P3; hallucinatory behavior)

iv. Item 6 (P6; suspiciousness/persecution)

Exclusion criteria

Exclusion Criteria:

  1. Any primary disorder other than schizophrenia within 12 months before screening (confirmed using Structured Clinical Interview for DSM-5, Clinical Trials Version (SCID-5-CT) at screening)
  2. History of treatment resistance to antipsychotic medications defined as inadequate response to two adequate courses of pharmacotherapy or previous clozapine treatment for treatment-resistant schizophrenia
  3. Participants who need to be treated with drugs that are known to be moderate and strong inhibitors and inducers will be excluded
  4. Participants taking a long-acting injectable antipsychotic could not have received a dose of medication in the last 12 weeks (24 weeks for INVEGA TRINZA®) before baseline

Other protocol-defined inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
142 participants (estimated)

Study arms

  • Experimental
    GXV813

    GXV813 administered orally.

    Drug: GXV813

  • Placebo comparator
    Placebo

    Placebo administered orally.

    Drug: Placebo

Interventions

  • DrugGXV813

    GXV813 administered orally.

  • DrugPlacebo

    Placebo administered orally.

06

What researchers measure

Primary outcomes

  1. Change from baseline in Positive and Negative Symptom Scale (PANSS) total score

    PANSS is a 30-item rating scale used to assess the positive, negative, and general psychopathy symptoms of schizophrenia. PANSS total score ranges from 30 to 120 , where a higher score indicates greater severity.

    Time frame: Baseline, Week 6

Secondary outcomes

  1. Number of participants with AEs

    Assessment of overall safety and tolerability of GXV813 versus placebo in adult inpatients with schizophrenia. This includes monitoring the occurrence and severity of adverse events, results of clinical laboratory tests, changes in vital signs, ECG findings, physical examinations.

    Time frame: Baseline to 6 weeks

  2. Participant clinically significant response

    Proportion of participants achieving a clinically significant response, defined as a ≥30% improvement in PANSS total score or a 1-point improvement in Clinical Global Impression-Severity (CGI-S) score from baseline at week 6, comparing GXV813 to placebo.

    Time frame: Baseline, week 6

  3. Change from baseline in PANSS positive sub-score

    Assessment of the effect of GXV813 versus placebo on positive symptoms of schizophrenia, measured by the change from baseline in the PANSS positive sub-score at week 6., which measures symptoms that reflect an excess or distortion of normal mental functions. Each item is rated from 1 (absent) to 7 (extreme).

    Time frame: Baseline, week 6

  4. Change from baseline in PANSS negative sub-score

    Assessment of the effect of GXV813 versus placebo on negative symptoms of schizophrenia, measured by the change from baseline in the PANSS negative sub-score (this sub-score is calculated by summing the ratings of seven items, each scored from 1 (absent) to 7 (extreme)) at week 6.

    Time frame: Baseline, week 6

  5. Change from baseline in Marder negative factor score

    Assessment of the effect of GXV813 versus placebo on negative symptoms of schizophrenia, measured by the change from baseline in the Marder (it is a five-factor structure derived from factor analysis of PANSS data) negative factor score at week 6.

    Time frame: Baseline, week 6

  6. Change from baseline in Clinical Global Impression- Severity (CGI-S) scale

    Assessment of the effect of GXV813 versus placebo on overall illness severity, measured by the change from baseline in the CGI-S scale at week 6. The CGI-S scale uses a 7-point rating system, where the highest score indicates greather severity.

    Time frame: Baseline up to week 6

  7. Assess the pharmacokinetics (PK) of GXV813: concentration-time curve (AUC)

    The Area Under the Curve (AUC) in pharmacokinetics represents the total drug exposure over time. It is the area under the plot of drug concentration in plasma versus time following administration.

    Time frame: Up to 6 weeks

  8. Assess the pharmacokinetics (PK) of GXV813: maximum observed plasma concentration (Cmax)

    Cmax is the highest concentration of a drug measured in plasma after administration and before the next dose.

    Time frame: Up to 6 weeks

07

Study locations

16 of 16 sites recruiting
  • Pillar Clinical Research LLC
    Bentonville, Arkansas 72712, United States
    Recruiting
    • · Contact501-307-1919
    • Leslie Smith · Principal investigator
  • CNRI Los Angeles LLC
    Pico Rivera, California 90660, United States
    Recruiting
    • Mohamed El-Gabalawy · Principal investigator
  • Segal Institute for Clinical Research
    Miami, Florida 33016, United States
    Recruiting
    • Rishi Kakar · Principal investigator
  • CenExel iResearch
    Decatur, Georgia 30030, United States
    Recruiting
    • Kimball Johnson · Principal investigator
  • Uptown Research Institute LLC
    Chicago, Illinois 60640, United States
    Recruiting
    • John Sonnenberg · Principal investigator
  • Pillar Clinical Research LLC
    Chicago, Illinois 60641, United States
    Recruiting
    • Scott Bartley · Principal investigator
  • Arch Clinical Trials LLC
    St Louis, Missouri 63141, United States
    Recruiting
    • Syed Junaid · Principal investigator
  • Novartis Investigative Site
    Sofia, BGR 1431, Bulgaria
    Recruiting
  • Novartis Investigative Site
    Haskovo, 6300, Bulgaria
    Recruiting
  • Novartis Investigative Site
    Kazanlak, 6100, Bulgaria
    Recruiting
  • Novartis Investigative Site
    Lovech, 5500, Bulgaria
    Recruiting
  • Novartis Investigative Site
    Plovdiv, 4002, Bulgaria
    Recruiting
  • Novartis Investigative Site
    Sliven, 8800, Bulgaria
    Recruiting
  • Novartis Investigative Site
    Sofia, 1377, Bulgaria
    Recruiting
  • Novartis Investigative Site
    Veliko Tarnovo, 5000, Bulgaria
    Recruiting
  • Novartis Investigative Site
    Vratsa, 3000, Bulgaria
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Jul 2027, 16 months after the start.

Of 57 industry-sponsored phase 2 interventional studies under Schizophrenia, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 32. This study's planned 16 months is below that.

Counting every sponsor, half of 101 studies reached it within 25 months; a quarter within 15 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 9, 2026
First posted
Mar 12, 2026
StartActual
Mar 16, 2026
Primary completionEst.
Jul 29, 2027
CompletionEst.
Jul 29, 2027
Last update
Jul 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07467993
Responsible party
Sponsor
First posted
Mar 12, 2026
Start date
Mar 16, 2026
Primary completion
Jul 29, 2027 (estimated)
Completion
Jul 29, 2027 (estimated)
Last update
Jul 29, 2026

Study contacts

Novartis Pharmaceuticals
Contact
novartis.email@novartis.com
1-888-669-6682
Novartis Pharmaceuticals
Contact
+41613241111

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion